On April 20, 2021, Janux Therapeutics announced the closing of a $125 million Series B financing led by RA Capital Management and joined by new investors BVF Partners L.P., EcoR1 Capital, Hartford HealthCare Endowment, Janus Henderson Investors, Logos Capital, Samsara BioCapital, and Surveyor Capital (a Citadel company). Janux’s existing investors, OrbiMed, Avalon Ventures, and Bregua, also participated. The proceeds of the financing will help support the advancement of Janux’s pipeline of next generation T cell engager immunotherapies, including a PSMA-TRACTr, EGFR-TRACTr, and TROP2-TRACTr, into initial proof of concept clinical trials.
A Wilson Sonsini Goodrich & Rosati team that was led by Laurie McNamara and included Mike Hostetler and paralegal Michelle Lee advised Janux on IP matters related to the transaction.
For more information, please see Janux Therapeutics' press release.